Wolfe Research has upgraded Abbott Laboratories (ABT) from Peer Perform to Outperform and set a new price target of $130. This analyst upgrade signals increased confidence in ABT's future performance, which could lead to positive short-term stock movement.
Wolfe Research analyst Mike Polark upgraded Abbott Laboratories (ABT) from 'Peer Perform' to 'Outperform' and announced a new price target of $130. This upgrade indicates a more bullish outlook from a prominent research firm, suggesting that the analyst believes ABT's stock will outperform its peers. For traders, this could signal a short-term buying opportunity as the market reacts to the positive sentiment. The long-term implications depend on whether ABT's fundamentals align with this upgraded outlook, but in the short term, it provides a positive catalyst for the stock.